Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma

AIM: We aim to develop a signature that could accurately predict prognosis and evaluate the response to immune checkpoint blockade (ICB) in bladder urothelial carcinoma (BLCA). METHODS: Based on comprehensive analysis of public database, we identified prognosis-related hub genes and investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Ya, Zhang, Yin Bin, Li, Yi, Su, Wang Hui, He, Shan, Pan, Shu Pei, Xu, Kun, Kou, Wei Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162857/
https://www.ncbi.nlm.nih.gov/pubmed/35664691
http://dx.doi.org/10.1155/2022/3342666
Descripción
Sumario:AIM: We aim to develop a signature that could accurately predict prognosis and evaluate the response to immune checkpoint blockade (ICB) in bladder urothelial carcinoma (BLCA). METHODS: Based on comprehensive analysis of public database, we identified prognosis-related hub genes and investigated their predictive values for the ICB response in BLCA. RESULTS: Among 69 common DEGs, three genes (AURKA, BIRC5, and CKS1B) were associated with poor prognosis, and which were related to histological subtypes, TP53 mutation status, and the C2 (IFN-gamma dominant) subtype. Three genes and their related risk model can effectively predict the response of immunotherapy. Their related drugs were identified through analysis of drug bank database. CONCLUSIONS: Three genes could predict prognosis and evaluate the response to ICB in BLCA.

Ejemplares similares